| INTRODUCTION
Patients with hepatitis C virus (HCV)-related cirrhosis are priority candidates for antiviral treatment, since they have an expected high rate of progression to liver decompensation, hepatocellular carcinoma (HCC), and eventually to death. 1 The achievement of sustained virological response (SVR) after antiviral treatment results in improved clinical outcomes, including reduced risk of liver events and HCC development, compared with lack of response. [2] [3] [4] [5] A recent prospective study by Bruno et al.
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, with a median follow-up of 9.6 years, evaluated 1802 patients with HCVrelated cirrhosis. Compensated patients with SVR on an interferon (IFN)-based regimen had a survival rate similar to that of the age-and gender-matched general population. These benefits attributable to SVR strongly suggest that eradicative treatment of HCV should be administered to patients with compensated HCV cirrhosis as early as possible, given also the recent introduction of IFN-free regimens based on direct antiviral agents (DAA) which allow SVR in the wide majority of patients. 2, [6] [7] [8] At the same time, that study confirmed that SVR is associated with lower, but not negligible, risk of HCC occurrence, 6 in line with other studies. [9] [10] [11] [12] To our knowledge, prospective studies with a follow-up allowing proper analysis of the outcome of patients who developed HCC after anti-HCV therapy-also in correlation with SVR or surrounding disease status-are lacking. In addition, an important clinical question still remains unanswered
13
: do patients who developed HCC benefit of HCV eradication by reducing, as a cause of death, the competing risk of cirrhosis progression that ultimately leads to end-stage liver disease (ESLD) independently from anti-HCC treatment?
The present retrospective analysis of a prospectively defined cohort assessed, in the group of cirrhotic patients reported by Bruno et al. 6 who had developed HCC during surveillance follow-up, overall survival (OS), rate of decompensation and HCC recurrence according to previous response to interferon (IFN)-based regimens, since HCC diagnosis.
Because treatment of cirrhosis with DAA has now become the standard of care, such information can assist in assessing priority for the vast allocation of financial and healthcare resources devoted to these patients. 6 ,14
| PATIENTS AND METHODS

| Patients
Surveillance data from three independent cohorts of Italian patients with HCV-related cirrhosis who were followed in tertiary liver centres were considered. 6 In brief, the first cohort (Milan-1) included consecutive patients with either compensated (Child-Pugh class A5-A6 according to 
Key points
• Studies on the long-term outcome of patients who developed HCC after anti-HCV therapy are lacking.
• HCC patients with SVR and compensated cirrhosis at diagnosis have prolonged OS than viraemic patients.
• ESLD is the main cause of death in viraemic patients; SVR patients do not die from it.
• This analysis represents a reference for further studies using DAA therapy, which are mandatory.
early HCC). Moreover, treatment selection took into account also other factors such as tumour site. 
| Statistical analysis
Two groups of patients were considered: (i) IFN-based treated patients with compensated cirrhosis at the time of HCC diagnosis who had prior achieved SVR; (ii) IFN-based treated patients who failed to achieve SVR with compensated cirrhosis at the time of HCC diagnosis (viraemic). Difference in the distribution of patients characteristics between the two groups was assessed by Fisher's Exact test.
The main study outcome was OS, calculated from the date of HCC diagnosis to last contact or death. OS curves were plotted using the Kaplan-Meier method and difference in survival between groups was compared with the log-rank test. Other outcomes were the development of hepatic decompensation and HCC recurrence; these outcomes were also evaluated by Kaplan-Meier analysis. We used Cox proportional hazards regression models to identify characteristics at the time of development of HCC associated with overall mortality, development of hepatic decompensation and HCC recurrence.
Multivariable models were constructed, in which factors that did not satisfy the criteria (P<.10) were removed in a step-down phase.
As further confirmatory analysis, patients with SVR at the time of HCC diagnosis were matched using propensity score for demographic criteria) with an equal number of viraemic patients. Fisher's exact test was used to assess differences in the distribution of characteristics between the two groups.
All analyses were two-tailed and P-values <.05 were considered significant. All analyses were performed with the sas software (version 9.2, Cary, NC, USA).
| RESULTS
| Patients
We identified 175 IFN-based treated patients with cirrhosis who developed an HCC during scheduled surveillance follow-up and were compensated at the time of HCC diagnosis. Of these, 156 had previously failed to achieve SVR after IFN-based therapy, and 19 had prior achieved SVR (Figure 1 ).
F I G U R E 1 Study flowchart
Patients characteristics at HCC diagnosis in the overall population and stratified according to SVR status are presented in 
| Overall survival
The median observation time was 3 years (range 0.1-24.1). Over this follow-up, 125 patients (71.4%) patients died; 47 patients (26.9%)
were still alive at the end of observation while three patients (1.7%)
were lost to follow-up. OS was significantly longer for patients with prior SVR than for viraemic patients (log-rank P=.004) (Figure 2 ). 
| Hepatic decompensation
Information about hepatic decompensation after the diagnosis of HCC was available for 165/175 patients: 98 developed decompensation.
The cumulative incidence of decompensation was significantly higher among viraemic patients than SVR patients (log-rank P=.01) (Figure 2 ). 
| Tumour recurrence
Tumour recurrence was evaluated among 119 compensated patients with HCC who received treatment with a curative intent, including surgery (n=20), trans-arterial chemoembolization (n=38), percutaneous ethanol injection (n=13) or radio-frequency thermal ablation (n=48) and available information on tumour recurrence.
Time to recurrence was similar for all treatment subtypes (data not shown, P=.32) but was significantly longer for SVR patients (logrank P=.01) (Figure 2 
| Propensity score analyses
The 19 patients with SVR and compensated cirrhosis at the time of HCC diagnosis were matched with 19 viraemic patients. None of the characteristics evaluated differed between the two groups (Table S1 ).
Patients with SVR had a significantly longer OS than viraemic patients (log-rank P=.049) ( Figure S1 ). In addition, causes of death differed significantly between the two groups: six patients with SVR ultimately died of HCC compared with four viraemic patients (log-rank P=.75)
while patients with SVR died for ESLD vs 7/19 (37%) matched viraemic patients (P=.004) ( Figure S2 ).
Patients with SVR had also lower rate of decompensation and tumour recurrence than viraemic patients but the difference was not significant ( Figure S1 ).
| DISCUSSION
This large retrospective analysis of a prospectively defined cohort, conducted in Italian reference liver centres, shows that patients treated with IFN with prior SVR and compensated cirrhosis have prolonged OS after the development of HCC compared with those without SVR. Remarkably, in our study, two of three compensated patients who previously attained SVR were alive 5 years after the development of HCC, while this figure dropped to one out of three in compensated patients who failed to achieve SVR at the time of IFN-based therapy.
This advantage is still evident 10 years after HCC diagnosis, as the majority of compensated patients with prior SVR were still alive.
A previous meta-analysis of patients who have undergone surgical resection/ablation of HCC and a retrospective cohort study of a pooled population of patients with and without SVR have suggested similar outcomes. 21, 22 However, to our knowledge the prolonged OS associated with SVR in HCV patients who developed HCC is supported here by the analysis of a prospective cohort for the first time.
Although the low rate of SVR reported in our study-which was expected in the pre-DAA era-should be taken into account, the prolonged OS associated with SVR achievement was confirmed at both univariable and multivariable analysis. In addition, we performed a propensity score analysis to account for the worsened clinical conditions observed in still viraemic patients, as compared with SVR patients. 
T A B L E 1 Patients characteristics at the time of development of hepatocellular carcinoma
T A B L E 1 (Continued)
The results of the propensity analysis confirmed those reported in the main analysis. Remarkably, the propensity analysis showed that the ultimate cause of death significantly differs between viraemic and SVR patients. As a matter of fact, none of patients with SVR died from ESLD, while this latter was the main cause of death in those who failed to achieve SVR. This evidence is in line with a previous analysis which indicated that the onset of HCC in viraemic patients, as well as those of portal hypertension-related complications, quickly accelerates the course of liver disease course to its final stage.
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More favourable outcomes were also reported in terms of incidence of hepatic decompensation and time to recurrence, which were improved in the SVR group compared with the viraemic group.
However, the benefit on time to recurrence associated with SVR was lost at the multivariable analysis. This could be due to the limited statistical power for this outcome, with only 16 SVR patients included for this analysis, and also to the noted correlation between HCV genotype and SVR. In a multivariate model unadjusted for HCV genotype, the association with SVR remained statistically significant (HR=0.46; 95% CI: 0.22-0.98; P=.04) after adjustment for other confounders (centre, number of lesions and BCLC).
We must also point out that we had sparse information on tumour recurrence and therefore definite conclusions cannot be made. With respect to recurrence, some recent notes of cautions derived from the results of a small retrospective study which reported a high rate of HCC recurrence after DAA treatment. 24 However, this study was at least partially flawed by a number of methodological and statistical concerns, and its findings were not confirmed in a large analysis of three prospective studies. [25] [26] [27] Prospective studies on this issue, potentially using new antiviral therapies, may provide more grounded results. Moreover, data on patients with more advanced HCC stages were lacking in our study, since they did not receive IFN-based treatment.
The prolonged OS in eradicated patients is easily justified by the lack of the competing risk of death attributable to concurrent liver dis- 
| Limitations of this study
This study is not without its limitations. The most important weakness is the small-but reliable-number of patients who achieved SVR, as expected in the pre-DAA era. In addition, the group of SVR patients included subjects who were treated before the occurrence of HCC.
Accordingly, patients overall presented more favourable characteristics when compared with those who did not achieve SVR (eg, lower
Child-Pugh class and MELD scores, less advanced tumour burden and higher rates of curative treatment) and who were likely to have a shorter duration of infection and less portal hypertension.
We also acknowledge an intrinsic selection bias originated by the use of IFN-based regimens, which have excluded the sickest patients or those with poorest conditions from, treatment.
Last, since IFN-based therapy was successful only in a limited number of patients, with more favourable characteristics, we may not be sure that our findings could fully apply to patients responding to the more recent DAA-based regimens.
Other limitations inherent to any observational retrospective study, such as poor reporting of data (eg, specific data on portal hypertension were not complete and hence this parameter was not considered; data on MELD scores were incomplete), should be also taken into account. In the next future, due to the widespread use of effective DAA treatments, the ratio of HCC will increase in SVR patients compared with those with virological failure. These patients will be similar to our 19 subjects, and therefore the information provided by our study might represent a reference standard for this population. It is true that the patients enrolled in our cohort were treated with IFN-based regimens. However, given that the biological meaning of SVR is independent from the actual treatment required to attain this goal, 12 we feel that our data may have a role also in the current DAA era. Indeed, in this illness in which two diseases concur, the virological eradication does cure cirrhosis, thus contributing to improve outcome of HCC patients, especially those with BCLC very early and early HCC and well-compensated cirrhosis. On the other hand, our data cannot be immediately transferred to patients with more advanced HCC or marginally compensated/decompensated cirrhosis.
Because patients in this study were treated years before HCC development and the benefits of HCV therapy are not immediate, new data using dedicated studies on DAA therapy which may support our suggestion appear mandatory. Noteworthy, this study might represent a key reference for further studies in this setting. a Hepatic decompensation was evaluated among 165 patients with compensated cirrhosis at the time of development of hepatocellular carcinoma (HCC).
Exposure
Overall mortality
Hepatic decompensation
b
Tumour recurrence was evaluated among 119 patients with compensated cirrhosis at the time of development of HCC who underwent curative treatment.
c Ablative interstitial therapies include transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI) or radio-frequency thermal ablation (RFTA).
T A B L E 2 (Continued)
